Vytorin Approval History

• FDA approved: Yes (First approved July 23rd, 2004)
• Brand name: Vytorin
• Generic name: ezetimibe/simvastatin
• Company: Merck/Schering-Plough Pharmaceuticals
• Treatment for: High Cholesterol, Familial Heterozygous, High Cholesterol, Familial Homozygous

Vytorin (ezetimibe/simvastatin) is a combination of ezetimibe (a lipid-lowering compound) and simvastatin (an HMG-CoA reductase inhibitor) for the treatment of high LDL cholesterol (LDL-C) in patients with primary hypercholesterolemia or mixed hyperlipidemia as adjunctive therapy to diet when diet alone is not enough.

FDA Approval History for Vytorin

Date	Article
Jan 25, 2012	New FDA Approved Labeling For Vytorin (ezetimibe/simvastatin) Includes Results From the Study of Heart and Renal Protection (SHARP) in Patients With Moderate to Severe Chronic Kidney Disease
Jul 23, 2004	Vytorin Merck/Schering-Plough Pharmaceuticals - Treatment for Cholesterol Reduction

See also...

Vytorin (ezetimibe/simvastatin) Consumer Information

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.